Results 81 to 90 of about 3,355,558 (275)

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals

Tobacco Induced Diseases, 2010
Background Nicotine replacement therapy (NRT) is the most common form of smoking cessation pharmacotherapy and has proven efficacy for the treatment of tobacco dependence. Although expectations of mild adverse effects have been observed to be independent
Edward J Mills, Ping Wu, Ian Lockhart, Kumanan Wilson, Jon O Ebbert   +4 more
doaj   +1 more source

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Observed and expected monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).

, 2013
Observed and expected monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).
Daniel F. Mackay (3708334), Jill P. Pell (238644), Sally Haw (339224)   +2 more
core   +1 more source

Engineering metal‐organic framework‐based smart porous nanoplatforms for targeted therapy and theranostic applications

Smart Molecules, EarlyView.
MOFs offer high porosity and tunability for biomedical applications, especially in cancer therapy via ROS generation and targeted delivery. Though toxicity, stability, and scalability remain key clinical challenges. Drug loading in MOFs exceeds 60%–70% with controlled release behavior.
Jagabandhu Bag, Subhasis Banerjee, Sabyasachi Banerjee, Sourav De, S. K. Ashok Kumar, Yan‐Jye Shyong, Subhankar Mukhopadhyay   +6 more
wiley   +1 more source

Harm perception among Swedish daily smokers regarding nicotine, NRT-products and Swedish Snus

Tobacco Induced Diseases, 2010
Background In Sweden NRT-products and Snus, are easily available and used as smoking cessation aids. However, most quit attempts are made without any cessation aids. The limited use of these products as cessation aids may be influenced by the way smokers
Tom Wikmans, Lars Ramström
doaj   +1 more source

Observed and predicted monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).

, 2013
Observed and predicted monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).
Daniel F. Mackay (3708334), Jill P. Pell (238644), Sally Haw (339224)   +2 more
core   +1 more source

A Survey Experiment on How Legal Status of Nicotine Products Influences Young Adults' Perceptions and Choices

Southern Economic Journal, EarlyView.
ABSTRACT This study investigates how sales bans influence young adults' perceptions and their interest in using combustible and non‐combustible nicotine products in Türkiye. Using a scenario‐based, between‐subjects experimental design, participants aged 18–30 were randomly assigned to one of four conditions: cigarettes or e‐cigarettes, framed as either
Asena Caner, Belgi Turan, Berna Tarı Kasnakoğlu, Yenal Can Yiğit, Donald S. Kenkel, Alan D. Mathios   +5 more
wiley   +1 more source

Median and IQR monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).

, 2013
Median and IQR monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–2009).
Daniel F. Mackay (3708334), Jill P. Pell (238644), Sally Haw (339224)   +2 more
core   +1 more source

Trends and patterns of dual use of combustible tobacco and e‐cigarettes among adults in England: A population study, 2016–2024

Addiction, Volume 120, Issue 4, Page 608-619, April 2025.
Abstract Background/Aims E‐cigarettes are frequently used by people who smoke. This study measured how the prevalence and patterns of smoking and vaping (‘dual use’) in England have changed as the vaping market has rapidly evolved. Design Representative monthly cross‐sectional survey, July 2016 to April 2024. Setting England.
Sarah E. Jackson, Sharon Cox, Lion Shahab, Jamie Brown   +3 more
wiley   +1 more source